Skip to main content
. 2018 Feb 15;194(6):520–532. doi: 10.1007/s00066-017-1257-z

Table 2.

Treatment characteristics

Total cohort (N = 100) Pneumonitis (N = 13)
Tumour site
Right breast 45 5
Left breast 55 8
Treatment postsurgery
RT alone S 2
RT + systemic therapy 92 11
Radiotherapy
RT BCW 75 5
RT BCW + S 8 1
RT BCW + S + P 17 7* (p < 0.005)
RT fields+systemic therapies
2FRT
RT alone BCW 6 0
RT BCW + CTX 4 0
RT BCW + H 57 5
RT BCW + CTX + Ab 3 0
RT BCW + CTX + H 2 0
RT BCW + CTX + Ab + H 3 0
3FRT
RT alone BCW + S 1 1
RT BCW + S + CTX 2 0
RT BCW + S + H 3 0
RT BCW + S + CTX + H 2 0
4FRT
RT alone BCW + S + P 1 1
RT BCW + S + P + CTX 1 0
RT BCW + S + P + H 4 1
RT BCW + S + P + CTX + Ab 1 0
RT BCW + S + P + CTX + H 7 2
RT BCW + S + P + CTX + Ab + H 3 3* (p < 0.001)
Systemic therapies
Chemotherapy
TEC 1 1
FEC 3 1
FEC + docetaxel (PACS 01) 9 0
EC + docetaxel 7 1
Doxorubicin + docetaxel 4 2
Carboplatinum + paclitaxel 4 0
Antibodies
Trastuzumab 5 0
Trastuzumab + pertuzumab 3 2
Anti-hormonal therapy
Aromatase inhibitors 46 6
Aromatase inhibitors + goserelin 3 0
Tamoxifen 6 0
Tamoxifen + goserelin 24 5* (p < 0.04)
Vaccines
Tecemotide (MUC1; Stimuvax) 2 1

RT radiotherapy, BCW breast and chest wall, S supraclavicular region, P parasternal region, CTX chemotherapy, Ab antibodies, H anti-hormonal therapy, EC epirubicin, cyclophosphamide, FEC 5-fluorouracil, epirubicin and cyclophosphamide, TEC docetaxel, epirubicin, cyclophosphamide, MUC1 a vaccine of MUC1 type

* statistically siginficant